Published in J Neurol Sci on June 11, 2011
Screening for HIV-associated peripheral neuropathy in resource-limited settings. Muscle Nerve (2013) 0.78
Cognitive impairment and psychiatric morbidity in HIV+ Zambians with new-onset seizure. Am J Trop Med Hyg (2014) 0.78
Evaluations of training programs to improve human resource capacity for HIV, malaria, and TB control: a systematic scoping review of methods applied and outcomes assessed. Trop Med Health (2017) 0.75
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology (2004) 3.44
Neurologic manifestations of HIV infection. Ann Intern Med (1994) 3.15
WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry (1994) 2.25
Mapping Africa's way into prominence in the field of neurology. Arch Neurol (2007) 1.97
Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol (2005) 1.87
Training and distribution of neurologists worldwide. J Neurol Sci (2002) 1.68
HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle Nerve (2010) 1.51
Neurologic services in the nations of Africa. Neurology (2005) 1.49
Neurology training programs worldwide: a world federation of neurology survey. J Neurol Sci (2006) 1.31
HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans. J Pain Symptom Manage (2010) 1.12
The International HIV Dementia Scale is a useful screening tool for HIV-associated dementia/cognitive impairment in HIV-infected adults in Yaoundé-Cameroon. J Acquir Immune Defic Syndr (2008) 1.06
Neurologic services in sub-Saharan Africa: a case study among Zambian primary healthcare workers. J Neurol Sci (2002) 1.00
Neurological disorders in AIDS and HIV disease in the northern zone of Tanzania. AIDS (1989) 0.95
Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya. Am J Trop Med Hyg (2010) 0.91
Barriers to care for patients with neurologic disease in rural Zambia. Arch Neurol (2000) 0.89
Neurology education and global health: my rotation in Botswana. Neurology (2007) 0.89
Evaluating the diagnostic capacity of a single-question neuropathy screen (SQNS) in HIV positive Zambian adults. J Neurol Neurosurg Psychiatry (2010) 0.89
Utility of quantitative sensory testing and screening tools in identifying HIV-associated peripheral neuropathy in Western Kenya: pilot testing. PLoS One (2010) 0.88
Second assessment of NeuroAIDS in Africa. J Neurovirol (2008) 0.84
Assessment of neuroAIDS in Africa. J Neurovirol (2005) 0.84
Assessment of neuroAIDS in the international setting. J Neuroimmune Pharmacol (2007) 0.83
Provision of care to people with epilepsy in Kenya. East Afr Med J (2007) 0.82
A neurologist in Zambia. Lancet Neurol (2002) 0.81
Peripheral neuropathy in AIDS patients at Kenyatta National Hospital. East Afr Med J (1996) 0.78
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis (2010) 3.46
Association between Mycoplasma genitalium and acute endometritis. Lancet (2002) 3.27
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
Creation of the AAN Global Health Section, part II: vision and goals. Neurology (2013) 2.67
HIV/AIDS stigma and refusal of HIV testing among pregnant women in rural Kenya: results from the MAMAS Study. AIDS Behav (2011) 2.59
Lifting the burden: the first 7 years. J Headache Pain (2010) 2.55
Evidence-based guidelines for mental, neurological, and substance use disorders in low- and middle-income countries: summary of WHO recommendations. PLoS Med (2011) 2.49
Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog (2013) 2.44
Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis (2006) 2.36
Migraine: the seventh disabler. J Headache Pain (2013) 2.35
Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med (2012) 2.06
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther (2010) 1.99
HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.94
Headache disorders are third cause of disability worldwide. J Headache Pain (2015) 1.93
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis (2007) 1.92
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis (2005) 1.91
The methodology of population surveys of headache prevalence, burden and cost: principles and recommendations from the Global Campaign against Headache. J Headache Pain (2014) 1.88
Text messaging to improve attendance at post-operative clinic visits after adult male circumcision for HIV prevention: a randomized controlled trial. PLoS One (2012) 1.85
Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis (2009) 1.82
Pregnancy in effectiveness trials of HIV prevention agents. Sex Transm Dis (2007) 1.79
Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials (2010) 1.75
Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol (2009) 1.70
Epilepsy-associated stigma in sub-Saharan Africa: the social landscape of a disease. Epilepsy Behav (2005) 1.70
Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog (2009) 1.66
Neurologic outcomes in retinopathy-negative cerebral malaria survivors. Neurology (2012) 1.66
Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials (2008) 1.65
Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain (2014) 1.63
Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. AIDS (2007) 1.61
Independent association of hygiene, socioeconomic status, and circumcision with reduced risk of HIV infection among Kenyan men. J Acquir Immune Defic Syndr (2006) 1.60
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis (2011) 1.59
The role of HIV-related stigma in utilization of skilled childbirth services in rural Kenya: a prospective mixed-methods study. PLoS Med (2012) 1.59
The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis (2011) 1.54
Integration of family planning services into HIV care and treatment in Kenya: a cluster-randomized trial. AIDS (2013) 1.52
The Global Campaign, World Health Organization and Lifting The Burden: collaboration in action. J Headache Pain (2011) 1.52
Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol (2005) 1.49
Neuroimaging findings in children with retinopathy-confirmed cerebral malaria. Eur J Radiol (2009) 1.47
Time to act on headache disorders. J Headache Pain (2011) 1.47
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47
Epilepsy is ubiquitous, but more devastating in the poorer regions of the world... or is it? Epilepsia (2014) 1.46
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.46
Association of attitudes and beliefs towards antiretroviral therapy with HIV-seroprevalence in the general population of Kisumu, Kenya. PLoS One (2009) 1.45
HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog (2011) 1.45
World Health Organization essential medicines lists: where are the drugs to treat neuropathic pain? Pain (2015) 1.44
Predictors of linkage to care following community-based HIV counseling and testing in rural Kenya. AIDS Behav (2012) 1.43
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS (2009) 1.40
Brain swelling and death in children with cerebral malaria. N Engl J Med (2015) 1.37
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis (2007) 1.36
Where did all the other non-communicable diseases go? BMJ (2011) 1.33
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr (2005) 1.32
Building capacity for cervical cancer screening in outpatient HIV clinics in the Nyanza province of western Kenya. Int J Gynaecol Obstet (2011) 1.32
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32
Male circumcision in the general population of Kisumu, Kenya: beliefs about protection, risk behaviors, HIV, and STIs. PLoS One (2010) 1.30
Integration of HIV Care with Primary Health Care Services: Effect on Patient Satisfaction and Stigma in Rural Kenya. AIDS Res Treat (2013) 1.29
Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther (2005) 1.28
Patient satisfaction with integrated HIV and antenatal care services in rural Kenya. AIDS Care (2012) 1.27
Zambian health care workers' knowledge, attitudes, beliefs, and practices regarding epilepsy. Epilepsy Behav (2006) 1.27
A prospective study of frequency and correlates of intimate partner violence among African heterosexual HIV serodiscordant couples. AIDS (2011) 1.26
Acceptability and feasibility of integration of HIV care services into antenatal clinics in rural Kenya: a qualitative provider interview study. Glob Public Health (2011) 1.26
Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol (2006) 1.24
Fertility intentions and interest in integrated family planning services among women living with HIV in Nyanza Province, Kenya: a qualitative study. Infect Dis Obstet Gynecol (2012) 1.23
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration. J Neurol (2007) 1.22
Potential impact of adjustment policies on vulnerability of women and children to HIV/AIDS in sub-Saharan Africa. J Health Popul Nutr (2005) 1.21
Is it time to rethink how neuropsychological tests are used to diagnose mild forms of HIV-associated neurocognitive disorders? Impact of false-positive rates on prevalence and power. Neuroepidemiology (2013) 1.17
The Global Burden of Disease survey 2010, Lifting The Burden and thinking outside-the-box on headache disorders. J Headache Pain (2013) 1.17
Short-term mobility and the risk of HIV infection among married couples in the fishing communities along Lake Victoria, Kenya. PLoS One (2013) 1.17
Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic Syndr (2014) 1.16
Shamba Maisha: a pilot study assessing impacts of a micro-irrigation intervention on the health and economic wellbeing of HIV patients. BMC Public Health (2010) 1.16
Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis (2011) 1.15
Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. J Infect Dis (2004) 1.14
NeuroInterp: a method for facilitating neuroimaging research on cerebral malaria. Neurology (2013) 1.13
Detection of novel organisms associated with salpingitis, by use of 16S rDNA polymerase chain reaction. J Infect Dis (2004) 1.12
Developmental outcomes in Malawian children with retinopathy-positive cerebral malaria. Trop Med Int Health (2010) 1.11
Migraine: the seventh disabler. Headache (2013) 1.10
Delay of antiretroviral therapy initiation is common in East African HIV-infected individuals in serodiscordant partnerships. J Acquir Immune Defic Syndr (2014) 1.09
Timed Gait test: normative data for the assessment of the AIDS dementia complex. J Clin Exp Neuropsychol (2006) 1.09
Social context and drivers of intimate partner violence in rural Kenya: implications for the health of pregnant women. Cult Health Sex (2013) 1.08
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One (2009) 1.08
Widow inheritance and HIV prevalence in Bondo District, Kenya: baseline results from a prospective cohort study. PLoS One (2010) 1.08
Children with retinopathy-negative cerebral malaria: a pathophysiologic puzzle. Pediatr Infect Dis J (2011) 1.08
Cost, cost-efficiency and cost-effectiveness of integrated family planning and HIV services. AIDS (2013) 1.07
Implementation and Operational Research: Effects of Antenatal Care and HIV Treatment Integration on Elements of the PMTCT Cascade: Results From the SHAIP Cluster-Randomized Controlled Trial in Kenya. J Acquir Immune Defic Syndr (2015) 1.06
Cerebrospinal fluid-based kinetic biomarkers of axonal transport in monitoring neurodegeneration. J Clin Invest (2012) 1.05
The epidemiology of primary headache disorders in Zambia: a population-based door-to-door survey. J Headache Pain (2015) 1.05
HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis (2005) 1.04
Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. BMC Infect Dis (2014) 1.04
Epilepsy care guidelines for low- and middle- income countries: From WHO mental health GAP to national programs. BMC Med (2012) 1.04
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses (2009) 1.04
An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. J Infect Dis (2013) 1.03
HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy. J Acquir Immune Defic Syndr (2016) 1.02